ORIGINAL ARTICLE Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome Florence Wong, S. Chris Pappas, Michael P. Curry, et al N Engl J Med 2021; 384:818-828DOI: 10.1056/NEJMoa2008290 Abstract BACKGROUND The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS We conducted a phase 3 trial to confirm the efficacy...

Original Investigation January 21, 2021 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Robert L. Gottlieb, Ajay Nirula, Peter Chen, et al JAMA. 2021;325(7):632-644. doi:10.1001/jama.2021.0202 Abstract Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for C...

ORIGINAL ARTICLE A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis Louise China, Nick Freemantle, Ewan Forrest, et al N Engl J Med 2021; 384:808-817 Abstract BACKGROUND Infection and increased systemic inflammation cause organ dysfunction and death in patients with decompensated cirrhosis. Preclinical studies provide support for an antiinflammatory role of albumin, but confirmatory large-scale clinical trials are lacking. Wh...

ORIGINAL ARTICLE Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Ivan O. Rosas, Norbert Bräu, Michael Waters, et al N Engl J Med February 25, 2021DOI: 10.1056/NEJMoa2028700 Abstract BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better ...

2020年引用最多论文  Understanding the disease ~ Zang H. et al. - Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Letter ~ Ruan Q. et al. ~Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Guidelines ~ Alhazzani W. et al. - Surviving Sepsis Campaign: guidelines on the management of cr...

ONLINE FIRST THIS WEEK(FREE ACCESS)  Original ~ Buetti N. et al. - COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA networkEditorial ~ Dale C.M. et al. - Leaving a mark: pressure injury research in the intensive care unitLetter ~ Proudfoot A.G. et al. - Rapid establishment of a COVID-19 critical care unit in a convention centre: the Nightingale Hospital London experienceCorrespondence ~ Meduri...

Research Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Viviane C Veiga, João A G G Prats, Danielle L C Farias, et al BMJ 2021; 372: n84 doi: https://doi.org/10.1136/bmj.n84 Abstract Objective To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open labe...

Original Investigation Caring for the Critically Ill PatientFebruary 23, 2021 Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial Jonathan E. Sevransky, Richard E. Rothman, David N. Hager, et al JAMA. 2021;325(8):742-750. doi:10.1001/jama.2020.24505 Abstract Importance Sepsis is a common syndrome with substantial morbidity and mortality. A ...

Original Investigation January 19, 2021 Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial Renato D. Lopes, Ariane V. S. Macedo, Pedro G. M. de Barros E Silva, et al JAMA. 2021;325(3):254-264. doi:10.1001/jama.2020.25864 Abstract Importance It is unknown whether angiotensin-c...

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial  RECOVERY Collaborative Group Lancet 2021; 397: 605–12  https://doi.org/10.1016/ S0140-6736(21)00149-5  Summary  Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID...